Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.